Recovery progress in the China business looks promising; Goldman Sachs maintains Buy on Sysmex

Overview

This report is Goldman Sachs' summary of a meeting on Sysmex (6869.T)'s China business. Meeting participants included a regional business planning head long based at Sysmex Shanghai and an IR representative with work experience in China. The report focuses on FY3/27 China business revenue guidance, demand for hematology testing, the strategy for Tier 3 hospitals, and the impact of China's healthcare cost-control policies on distributor inventory, testing volume, and pricing.

Core views

Goldman Sachs' core view is that although Sysmex's China business still faces revenue pressure in FY3/27, the main headwinds are gradually peaking. Management has incorporated the impact of test price standardization into guidance and expects the China business to decline 20% in local currency terms for the full year; 1H will face heavier pressure from the principle of minimum necessity, distributor inventory adjustments, and VBP, while pressure should ease somewhat in 2H. As the China business recovers and the company's overall earnings return to growth, Goldman Sachs maintains its Buy rating.

Analysis framework

The report is mainly based on company meeting discussions and management comments, combined with analysis of policy impacts, volume trends, the distributor inventory cycle, hospital client strategy, and relative valuation methods, to assess the recovery path of the China business and the stock's upside potential.

Methodology notes

• Company meeting summaryManagement interviews and operating trend validation

  Validate changes in the China business through direct discussions with company management and IR.

  The report breaks the meeting highlights into revenue guidance, testing volume, channel inventory, policy impacts, and future hospital strategy to assess whether recovery in the China business is progressing.

• Policy impact analysisBreakdown of the impact of China's healthcare cost-control policies

  Differentiate the timing of impacts from distributor inventory adjustments, the principle of minimum necessity, VBP, and test price standardization.

  Goldman Sachs focuses on whether these policies have already been reflected in FY3/27 guidance, and whether the impact will peak in 1H and ease in 2H.

• Valuation methodEV/EBITDA relative valuation

  Based on the global medical technology sector FY3/28E average EV/EBITDA of 11.0x, with a 20% discount applied.

  The 12-month target price of ¥1,700 is derived by applying a discount to the sector average valuation, reflecting a balance between China headwinds and the company's recovery prospects.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Sysmex (6869.T)

  The covered name in the report, a Japan-listed medical technology and in vitro diagnostics company, with the China business as the core topic of this meeting.

  Strengths

  Stable testing volume per instrument in the core hematology segment; the company maintains share in Tier 3 hospitals and is attempting to provide higher value-added services positioned as a laboratory partner; global medical technology experience can be applied to serving hospital clients in China.

  Weaknesses

  The China business is still expected to decline 20% YoY in FY3/27; 1H is more heavily affected by policy and channel inventory; some high-priced testing areas face pressure from price standardization.

  Comparison

  Compared with Japan and other regions, the proportion of D-dimer testing within standard hemostasis testing in China has fallen from about 60% to about 40%, close to levels in other regions, indicating that some policy adjustments have already been reflected in demand.

  Risks

  China healthcare cost-control policies, broader VBP expansion, test price standardization, distributor restructuring, local competition, foreign exchange, supply chain issues, and weak capital spending.

Key data

• Report date2026-06-16The report was published on June 16, 2026 Japan time.
• RatingBuyGoldman Sachs maintains a Buy rating on Sysmex.
• 12-month target price¥1,700Based on the global medical technology sector FY3/28E average EV/EBITDA of 11.0x with a 20% discount applied.
• Disclosed price¥1,413The Sysmex price listed in the company's specific disclosure.
• FY3/27 China business revenue guidanceYoY decline of 20%In local currency terms, incorporating the expected impact of test price standardization.
• FY3/27 1H China business revenue assumptionYoY decline of 28%Mainly affected by the principle of minimum necessity, distributor inventory adjustments, and VBP.
• FY3/27 2H China business revenue assumptionYoY decline of 10%Mainly reflects the impact of test price standardization.
• Change in D-dimer testing mixFrom about 60% down to about 40%The company believes this ratio is already close to levels in Japan and other regions, supporting the view that the impact of the principle of minimum necessity is being gradually absorbed.
• Timing of test price standardization impactLate 2026 or laterThe company expects pilot programs in some regions first, followed by nationwide expansion, so the full earnings impact will not appear immediately.

Impact & implications

If the impacts of distributor inventory adjustments and cost-control policies are absorbed as expected in 1H FY3/27, the decline in Sysmex's China business may narrow in 2H, and the market may refocus on the resilience of its core hematology business and the recovery in overall company earnings. However, test price standardization, channel restructuring, and competition from local manufacturers may still affect the pace of recovery.

Risks

• Test price standardization may lead to sharp price declines for some testing items.
• Although distributor inventory adjustments are expected to be absorbed in 1H FY3/27, channel restructuring risk remains.
• The principle of minimum necessity may expand into areas such as immunochemistry, where bundled testing is more common.
• Intensifying competition from local manufacturers in emerging markets may create downward pricing pressure.
• Geopolitics, supply chain changes, global healthcare system cost controls, foreign exchange volatility, inflation, and weak capital spending are all downside risks.

What to watch

• Whether China revenue bottoms as expected in 1H FY3/27.
• The policy direction, pilot regions, and nationwide rollout pace of test price standardization.
• Distributor inventory levels and progress on potential distributor restructuring.
• Whether expansion among Tier 3 hospital clients can stabilize hematology testing market share.
• Whether the decline in the China business narrows from 28% in 1H to around 10% in 2H.
• Whether the company's overall earnings return to growth and drive valuation recovery.